Recent 8-K filings for ELV

• May 13, 2026, 4:07 PM ET other material materiality 0.15 neutral item 5.07

  Elevance Health annual meeting: directors elected, exec pay approved, shareholder proposal defeated

  Gail K. Boudreaux, Robert L. Dixon Jr., and Deanna D. Strable elected as directors for three-year terms.

• April 22, 2026, 7:59 PM ET earnings materiality 0.78 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Elevance Health Q1 adj EPS $12.58 beats; raises FY2026 adj EPS guidance to at least $26.75

  Q1 operating revenue $49.5B (+1.5% YoY); diluted EPS $8.00, adjusted diluted EPS $12.58 (includes ~$1 non-recurring investment income).

• March 10, 2026, 7:59 PM ET other material materiality 0.70 neutral item 7.01

  Elevance Health reaffirms FY2026 adj. EPS at least $25.50, benefit expense ratio ~90.2%

  Reaffirms adjusted shareholders' earnings for FY2026 at least $25.50 per diluted share.

• March 2, 2026, 6:59 PM ET regulatory materiality 0.70 negative item 8.01

  CMS proposes sanctions suspending Elevance Medicare Advantage enrollment over risk adjustment data issues

  CMS notified Elevance of intent to impose sanctions suspending MA-PD enrollment and certain communications effective March 31, 2026 unless resolved.

• February 26, 2026, 6:59 PM ET leadership materiality 0.60 neutral item 5.02item 7.01item 9.01

  CFO Mark Kaye adds Carelon oversight; Haytaian transitions; FY2026 guidance reaffirmed

  Peter Haytaian steps down as Carelon President effective May 4, 2026; will serve as Special Advisor through Dec 31, 2026.

• January 28, 2026, 6:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  Elevance Health Q4 adj. EPS $3.33 on higher medical costs; FY2026 adj. EPS guide $25.50, down from $30.29

  Q4 2025 GAAP diluted EPS $2.47; adjusted $3.33; operating revenue $49.3B (+10% YoY).

• December 10, 2025, 6:59 PM ET leadership materiality 0.30 neutral item 5.02item 9.01

  Elevance Health elects Amy Schulman as independent director effective Jan 12, 2026

  Amy Schulman, Managing Partner at Polaris Partners, joins Elevance Health board.

• November 10, 2025, 6:59 PM ET other material materiality 0.50 neutral item 7.01

  Elevance Health reaffirms FY2025 EPS guidance of $24.70 ($30.00 adj.) and 90.0% benefit expense ratio

  Full-year 2025 GAAP EPS expected ~$24.70, including ~$5.30/sh net unfavorable items.

• October 21, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Q3 revenue $50.1B (+12% YoY), GAAP EPS $5.32, adj. EPS $6.03; FY guidance reaffirmed

  Health Benefits operating revenue $42.2B (+10% YoY), operating margin 1.4%, medical membership ~45.4M.

• September 15, 2025, 7:59 PM ET debt materiality 0.60 neutral item 8.01item 9.01

  Elevance Health closes $3B multi-tranche note offering; proceeds to refinance near-term debt

  Issued $750M 4.000% notes due 2028, $750M 4.600% notes due 2032, $1,000M 5.000% notes due 2036, $500M 5.700% notes due 2055.

• September 4, 2025, 7:59 PM ET earnings materiality 0.50 neutral item 7.01

  Reaffirms full-year 2025 adjusted EPS guidance of $30.00 and benefit expense ratio of 90.0%

  Reaffirms FY2025 GAAP EPS guidance of ~$24.10, including ~$5.90 net unfavorable items.

• July 28, 2025, 7:59 PM ET leadership materiality 0.30 neutral item 5.02item 9.01

  Elevance Health elects Steven H. Collis to board, effective Aug 1, 2025

  Steven H. Collis, Executive Chairman of Cencora, elected as independent director effective Aug 1, 2025.

• July 17, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Elevance Health cuts FY2025 adjusted EPS guidance to ~$30 on elevated medical costs

  Operating revenue $49.4B (+14.3% YoY); diluted EPS $7.72, adjusted diluted EPS $8.84.

• May 28, 2025, 7:59 PM ET other material materiality 0.50 neutral item 7.01

  Elevance reaffirms FY2025 adjusted EPS guidance of $34.15-$34.85

  FY2025 GAAP EPS guidance $28.30-$29.00, including ~$5.85 net unfavorable items.

• May 14, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Elevance Health shareholders elect directors, approve say-on-pay, reject DEI proposal

  Directors DeVore (185.8M for), Jallal (180.8M for), Schneider (184.6M for) elected to three-year terms.

• April 22, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Elevance Health Q1 2025 revenue $48.8B (+15.4% YoY); adj. diluted EPS $11.97; reaffirms FY guidance

  Operating revenue $48.8B (+15.4% YoY); diluted GAAP EPS $9.61, adjusted diluted EPS $11.97.

• April 17, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01

  Elevance Health pre-announces Q1 2025 adjusted EPS of $11.97; reaffirms FY guidance

  Q1 GAAP EPS of $9.61, includes $2.36/share net unfavorable items; adjusted EPS $11.97.

• March 10, 2025, 7:59 PM ET other material materiality 0.50 neutral item 7.01

  Elevance Health reaffirms FY 2025 adjusted EPS guidance of $34.15-$34.85

  Reaffirms 2025 shareholders' earnings per diluted share of $30.40-$31.10, including ~$3.75 net unfavorable items.

• January 23, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Elevance Health Q4 2024 adjusted EPS $3.84, FY 2025 guidance $34.15-$34.85; dividend raised 5% to $1.71

  Q4 operating revenue $45.0B (+6% YoY); FY revenue $175.2B (+3%).

• October 31, 2024, 7:59 PM ET debt materiality 0.60 neutral item 8.01item 9.01

  Elevance Health closes $5.2B multi-tranche notes offering; proceeds for general corporate purposes

  Issued $5.2B aggregate principal across six series: 2026 (4.500%), 2030 (4.750%), 2031 (4.950%), 2035 (5.200%), 2055 (5.700%), 2064 (5.850%).

• October 17, 2024, 7:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01

  Elevance Health Q3 adjusted EPS $8.37; FY2024 guidance cut to ~$33.00

  Q3 2024 operating revenue $44.7B, up $2.2B YoY; diluted EPS $4.36 GAAP, adjusted $8.37.

• July 17, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Elevance Health Q2 diluted EPS $9.85 (+26% YoY); revenue $43.2B, down $0.2B

  Adjusted diluted EPS $10.12 (+12% YoY); GAAP EPS at least $34.05 for FY2024, adjusted at least $37.20.

• June 12, 2024, 7:59 PM ET other material materiality 0.50 neutral item 7.01

  Elevance Health reaffirms FY2024 net income >$34.05, adjusted >$37.20 per share

  Net income guidance for FY2024 greater than $34.05 per diluted share including approximately $3.15 per share of net unfavorable items.

• May 30, 2024, 7:59 PM ET debt materiality 0.70 neutral item 8.01item 9.01

  Elevance Health closes $2.6B senior notes offering in three tranches

  Issued $600M 5.150% notes due 2029, $1B 5.375% notes due 2034, $1B 5.650% notes due 2054.

• May 15, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×4

  Elevance Health shareholders elect directors, approve executive pay, ratify E&Y, reject political spending proposal

  Lewis Hay, III, Antonio F. Neri, and Ramiro G. Peru were elected as directors for three-year terms with over 183 million votes each.

• April 18, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Elevance Health Q1 diluted EPS $9.59 (+15.5%); raises FY2024 adj. EPS guidance to >$37.20

  Q1 operating revenue $42.3B (+0.9% YoY); diluted EPS $9.59 (+15.5%); adjusted diluted EPS $10.64 (+12.5%).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event earnings

5 positive 4 negative 17 neutral

source · ELV on sec.gov